![[aggregator] downloaded image for imported item #98205](https://newsview.top/wp-content/uploads/2026/07/woman-glp1-medication-1024x576.jpg "Big Medicare change slashes weight-loss drug costs for eligible seniors")
This post was originally published on this site.
Novo Nordisk to slash Wegovy, Ozempic list prices
Board certified rheumatologist Dr.Mahsa Tehrani discusses Novo Nordisk’s decision to dramatically cut the U.S.list prices for its popular diabetes and weight-loss drugs Ozempic and Wegovy on ‘America Reports.’
Millions of Medicare beneficiariesstruggling with obesitycould soon see the cost of weight-loss drugs plummet, as a new federal pilot program launching July 1 expands access to GLP-1 medications like Wegovy and Zepbound for eligible seniors.
Through a new trial called Medicare GLP-1 Bridge, the federal government is now offering a selection of the brand-name medications to certain Medicare and Medicare Advantage beneficiaries for $50 a month, The Associated Press reported.
Thecovered medicationsinclude drugmaker Eli Lilly’s Foundayo tablets and Zepbound KwikPens and Novo Nordisk’s Wegovy injections and tablets, all of which have been FDA-approved for weight loss, according to the report.
OZEMPIC USERS MAY BE MAKING A MAJOR WEIGHT-LOSS MISTAKE, NEW STUDY SUGGESTS
The temporary program is set to run until the end of 2027.
This is the first time GLP-1s (glucagon-like peptide-1 receptor agonists) will be covered by insurance when usedsolely for weight loss.
A new federal pilot program launching July 1 expands access to GLP-1 medications like Wegovy and Zepbound for eligible seniors.(iStock)
Prior to this new Medicare pilot, seniors who wanted to access GLP-1s for obesity alone paid about $1,350-$1,650 per month for Novo Nordisk’s Wegovy (semaglutide) and about $1,086 monthly for Lilly’s Zepbound (tirzepatide).However, both manufacturers offered some cash-pay options that significantly reduced those prices for eligible patients.
GLP-1 WEIGHT LOSS DRUGS ARE RESHAPING THE BRIDAL INDUSTRY AS SHOPS RUSH ORDERS AND REQUIRE NEW WAIVERS
There are some parameters surrounding the coverage — older adults must have had a body mass index (BMI) of 35 or higher when they started GLP-1 therapy, or a BMI of 27 or higher alongside another health condition, such as a pastheart attack or strokeor prediabetes.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Those who already have insurance coverage for other diseases,such as diabetesand sleep apnea, are not eligible for the program.
Through a new trial called Medicare GLP-1 Bridge, the federal government is now offering a selection of the brand-name medications to certain Medicare and Medicare Advantage beneficiaries for $50 a month.(iStock)
There are more than 70 million Americans currently enrolled in Medicare, 10 million of whom are overweight or obese, according to Juliette Cubanski, vice president and director of the program on Medicare policy at the healthcare research nonprofit KFF.
“For many older Americans living with obesity, this is a moment they and their families have been waiting for,” Jamey Millar, Novo Nordisk’s executive vice president of U.S.operations, said in a press release.
“The Medicare GLP-1 Bridge program offers a new, affordable path to an FDA-approved treatment that was previously not covered.”
“The sheer cost ofthese medicationsis a huge barrier to access,” he said in a call with reporters.“That ends today.”
Prior to this new Medicare pilot, seniors who wanted to access GLP-1s for obesity alone paid about $1,350-$1,650 per month for Novo Nordisk’s Wegovy (semaglutide) and about $1,086 monthly for Lilly’s Zepbound (tirzepatide). (iStock)
Oz told reporters that CMS plans to “carefully track participation and outcomes” to see whether an extension of the Bridge program or another solution is the best way to move forward.He told AP afederal lawpermanently allowing the coverage is “not essential right now” but something “for Congress to debate amongst themselves.”
“We can’t decide what’s going to happen long term with Bridge until we see some of the data,” he said, adding that there are ongoing talks with drug companies to lower costs.
onelink.me/xLDS?pid=AppArticleLink&af_web_dp=https%3A%2F%2Fwww.
One potential concern is thatolder patientstend to have more adverse effects to medication in general , according to Dr.Micah Eimer, a clinical assistant professor of cardiology at the Northwestern University Feinberg School of Medicine.
“Specifically, in our research, older patients on blood pressure medications were more likely to experience hypotensive side effects, such as fainting and dizziness, after starting a GLP-1,” he said in a statement.
The Associated Press contributed to this report.
![[aggregator] downloaded image for imported item #83025](https://newsview.top/wp-content/uploads/2026/05/two-friends-walking-having-deep-conversation-1024x576.gif "5 common walking mistakes that could hurt your progress, according to an expert")
![[aggregator] downloaded image for imported item #83018](https://newsview.top/wp-content/uploads/2026/05/upscale-expensive-water-trend-1024x576.jpg "Filtered water at specific ages could add months to your lifespan decades later, new study finds")
![[aggregator] downloaded image for imported item #83327](https://newsview.top/wp-content/uploads/2026/05/young-woman-headache-kitchen-fox-news-001-1024x576.jpeg "Experimental Alzheimer’s drug could reduce alcohol withdrawal damage, researchers say")
![[aggregator] downloaded image for imported item #83320](https://newsview.top/wp-content/uploads/2026/05/fox-news-health-dementia-study-sitting-1024x576.jpg "One type of sitting may pose greater dementia risk than another, study suggests")